semaglutide and autoimmune disorders Weight loss, disease activity, patient reported outcomes in patients with musculoskeletal and diseases taking weight loss medications: a retrospective cohort study Anti-inflammatory benefits of semaglutide: State
Description
A., Mandarino, L
doi: 10.1111/dom.13162
CONCLUSIONS During IMD therapy for obesity, preserving muscle mass and function is an essential treatment goal alongside reducing excess and abnormal adiposity
The difference reflects both absorption efficiency and the weekly dosing advantage of injections, which maintain steadier hormone levels throughout treatment
Notably, this study included broad range of GLP-1 drugs, including much older GLP-1s that have far lower anti-obesity, anti-craving, and anti-addictive effects: abiglutide (Eperzan, Tanzeum), dulaglutide (Trulicity), exenatide (Byetta, Bydureon), liraglutide (Victoza, Saxenda), lixisenatide (Adlyxin, Lyxumia), semaglutide (Ozempic, Rybelsus, Wegovy) and tirzepatide (Mounjaro) Its possible that the associations that were found would be even stronger if the study had looked exclusively at semaglutide and tirzepatide, which are the current best-in-class options for weight loss
The medication also slows gastric emptying, meaning food stays in your stomach longer and you feel fuller on smaller portions
